Agios Pharmaceuticals (NASDAQ:AGIO) Insider Tsveta Milanova Sells 2,932 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,932 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the sale, the insider directly owned 29,190 shares in the company, valued at approximately $790,757.10. The trade was a 9.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $27.18 on Friday. The company has a market capitalization of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89. The company has a 50-day simple moving average of $32.20 and a two-hundred day simple moving average of $35.96. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company’s revenue was up 43.3% compared to the same quarter last year. During the same period last year, the business earned $16.22 EPS. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AGIO. Wall Street Zen downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Royal Bank Of Canada downgraded Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $57.00 to $28.00 in a research note on Wednesday, November 19th. Bank of America upped their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Leerink Partnrs raised Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 20th. Finally, JPMorgan Chase & Co. dropped their price target on Agios Pharmaceuticals from $37.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $38.89.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of large investors have recently bought and sold shares of AGIO. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals in the 1st quarter worth approximately $40,000. First Horizon Corp purchased a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at $45,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 320 shares during the period. Quantbot Technologies LP purchased a new position in shares of Agios Pharmaceuticals during the third quarter worth $79,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth $133,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.